Novo Nordisk Shares Plunge on Insulin's FDA Failure

Feb. 11 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk shares have fallen the most in a decade as the company's new insulin drug Tresiba has failed to win FDA approval in the United States. She speaks on Bloomberg Television's "The Pulse."

Traders Bet on Brazil Despite Turmoil
41:24 - Bloomberg's Scarlet Fu and Joe Weisenthal take a look at two charts that show how traders are betting on Brazil. They speak on "What'd You Miss?" (Source: Bloomberg)
  • S&P 500 Winners and Losers for 05/22
  • Timmermans Says EU Is Not Trying to Punish U.K.
  • Trouble Brews in Subprime Auto Loan Market